Drug intelligence / Profile preview

FTX008762

Development stage: Preclinical
Lead developer: Fountain Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

FTX008762 is an orally bioavailable small molecule developed by Fountain Therapeutics for the treatment of muscle-wasting conditions. It is primarily being investigated for GLP-1 agonist-induced lean tissue atrophy—a side effect associated with weight-loss drugs like semaglutide and tirzepatide—as well as age-associated sarcopenia. The compound was identified using Fountain's AI-driven platform, which screens for drugs that can reverse cellular aging. FTX008762 targets a novel, undisclosed biological pathway to preserve muscle mass and function. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on FTX008762.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FTX008762.

Explore the full profile